Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.

In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

The approval marks the first new pharmacologic treatment in motion sickness in over four decades. The US Food and Drug ...

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

J&J anticipates earnings dilution in the fourth quarter of 2025 and into 2026. Credit: Skorzewiak/Shutterstock.com. Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a ...